Search this site
Embedded Files
Skip to main content
Skip to navigation
TTBF
Home
R&D Day 2020
TTBF message before AGM 2020
Compensation/TSR
TTBF message before EGM
Retail shareholders
Views of TTBF
EGM Circular
Open Letters
Investor Meetings
Hemophilia
EBITDA
Open Letter 10.01.18
R&D pipeline
Rare disease
about TTBF
Damage caused by Shire deal
Reference
R&D Day 2019
Shire Q3 2018
Q2 2018 Takeda
Takeover Code
Weber letter to shareholders
Convocation of Ordinary GMS
Takeda 2018/3 results
Shire: 1Q (2018/3) results
prucalopride
TTBF
Home
R&D Day 2020
TTBF message before AGM 2020
Compensation/TSR
TTBF message before EGM
Retail shareholders
Views of TTBF
EGM Circular
Open Letters
Investor Meetings
Hemophilia
EBITDA
Open Letter 10.01.18
R&D pipeline
Rare disease
about TTBF
Damage caused by Shire deal
Reference
R&D Day 2019
Shire Q3 2018
Q2 2018 Takeda
Takeover Code
Weber letter to shareholders
Convocation of Ordinary GMS
Takeda 2018/3 results
Shire: 1Q (2018/3) results
prucalopride
More
Home
R&D Day 2020
TTBF message before AGM 2020
Compensation/TSR
TTBF message before EGM
Retail shareholders
Views of TTBF
EGM Circular
Open Letters
Investor Meetings
Hemophilia
EBITDA
Open Letter 10.01.18
R&D pipeline
Rare disease
about TTBF
Damage caused by Shire deal
Reference
R&D Day 2019
Shire Q3 2018
Q2 2018 Takeda
Takeover Code
Weber letter to shareholders
Convocation of Ordinary GMS
Takeda 2018/3 results
Shire: 1Q (2018/3) results
prucalopride
FY2018/3 results for Takeda
qr2017_q4_p01_en.pdf
Report abuse
Report abuse
